Gland Pharma adds investor meetings for June 04, 2026
Gland Pharma Limited has updated its schedule for meetings with analysts and institutional investors in June 2026. The company added new sessions with BofA and Emkay Global for June 04, 2026, supplementing previously announced interactions with Carnelian Asset Management and ICICI Securities later in the month. The schedule remains subject to change due to exigencies on the part of investors, analysts, or the company.

*this image is generated using AI for illustrative purposes only.
Gland Pharma Limited has updated its schedule for meetings with analysts and institutional investors in June 2026. The company added new sessions with BofA and Emkay Global for June 04, 2026, supplementing previously announced interactions with Carnelian Asset Management and ICICI Securities later in the month.
The updated schedule includes a group meeting arranged by BofA and a one-on-one session with Emkay Global. These additions follow the earlier disclosed plan to host Carnelian Asset Management for a one-on-one meeting and participate in the ICICI Securities India Investor Conference 2026.
The company noted that the schedule remains subject to change due to exigencies on the part of investors, analysts, or the company.
The following table outlines the confirmed schedule:
| Date | Investor/Analyst/Fund Name | Type of Meeting |
|---|---|---|
| June 01, 2026 | Carnelian Asset Management | One-on-One Meeting |
| June 04, 2026 | Group Meeting arranged by BofA | Group Meeting |
| June 04, 2026 | Emkay Global | One-on-One Meeting |
| June 08, 2026 | ICICI Securities India Investor Conference 2026 | One-on-One & Group Meetings |
Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer, signed the intimation on May 29, 2026.
Historical Stock Returns for Gland Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.96% | -3.28% | +27.50% | +26.40% | +38.50% | -29.36% |
What key topics or strategic updates is Gland Pharma likely to discuss during these investor meetings?
How might these investor interactions influence Gland Pharma's stock performance in the near term?
Could the increased engagement with analysts signal upcoming corporate actions or new business developments?


































